Connecting Innovation to Purpose

22 CRB-701: A differentiated clinical development approach to competitors Proprietary insights are driving indication selection for CRB-701 mUC Other Nectin-4 solid tumors New reality of Padcev® + Keytruda Ⓡ 1L therapy Emerging clinical data from current dose escalation is informative Under-served niche mUC populations remain and are attractive targets Focus on unexplored Nectin-4 solid tumors

View entire presentation